Biocon’s arm transfers branded formulations business in India to Eris Lifesciences

03 Apr 2024 Evaluate

Biocon’s subsidiary -- Biocon Biologics has completed the transaction of transfer of its branded formulations business in India to Eris Lifesciences on a slump sale basis. The slump sale is on a standalone basis and not pursuant to amalgamation/merger. The transaction is completed on April 2, 2024. 

The consideration received from such sale/disposal is Rs 1,242 crore including working capital adjustments. Eris Lifesciences (Eris) is a publicly listed Indian pharma company with a pure-play domestic branded formulations business model.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.


Biocon Share Price

306.00 -1.00 (-0.33%)
29-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.